Answer

IFF Scent recovery drivers, H2 evolution for Fine Fragrance & Consumer Fragrance, and R&D plan to support 2027

1) Drivers of Scent’s recovery

A. Strong underlying execution across Fine Fragrance, Consumer Fragrance, and Fragrance Ingredients

In Scent, the company delivered 8% sales growth in Q2, with performance driven by double-digit growth in Fragrance Ingredients and high single-digit growth in Consumer Fragrance, while Fine Fragrance grew low single digits (and this was inclusive of Middle East impacts). ¹
Management attributed profitability improvement to volume growth and productivity gains, with Scent EBITDA increasing 5% to $134 million. ¹

B. Fragrance Ingredients: synthetics capture + normalization toward higher-value ingredients

In Q2, Fragrance Ingredients grew north of 20%, but management emphasized that part of the strength reflected a favorable year-over-year comparison versus an earlier period that was down 10% or more. ²
They also said the team strategically leveraged the synthetics portfolio to capture sales amid macroeconomic conditions, including supply chain disruptions and higher Brent crude prices. ²
For the recovery narrative going forward, management expects this to normalize in the second half, shifting back toward higher value-added ingredients versus traditional synthetics—i.e., the near-term volume/mix tailwind should fade as the business rotates toward its longer-run product mix. ²

C. Fine Fragrance: operational management of Middle East volatility with a strong Q4 setup

Management stated the team managed Fine Fragrance challenges in the Middle East, resulting in growth that finished slightly positive versus expectations of mid-single-digit decline entering the quarter. ²
Looking forward, they described softer Q3 expectations and recovery starting in Q4, explicitly tying part of the quarterly shape to comps—Q3 last year Fine Fragrance grew 20%, creating a difficult year-over-year comparison. ²

D. Consumer Fragrance: R&D capability rebuild + go-to-market execution to regain share

On Consumer Fragrance, management credited a program to rebuild R&D capability and rebuild the go-to-market approach with customers and to drive market share gains. ³
This is consistent with their broader R&D stance (pipeline, perfumers, molecules/delivery systems) discussed as improving after being “not what it should have been” about 2.5 years ago. ⁴

E. R&D capability and pipeline progress is a concrete operational recovery lever

Management highlighted that 2.5 years ago the R&D pipeline was “not what it should have been,” but that today it is “very strong,” with leading-edge perfumers developing new Fine Fragrances and Consumer Fragrances and a strong pipeline of molecules and delivery systems. ⁴
They emphasized a continued commitment to strengthening the business: “strengthening our strengths and addressing our gaps” while remaining optimistic about the future. ⁴

2) How Fine Fragrance and Consumer Fragrance will evolve in H2

Fine Fragrance (Scent): mid-single-digit range in H2 with Q3 softer and Q4 stronger

Management summarized the directional trajectory: “a little bit softer in Q3, but a stronger Q4” for Fine Fragrance. ³
On a second-half basis, they expect Fine Fragrance to be in the mid-single-digit growth range, supported by strong comparables and an improving second-half trajectory. ³
Additional context: Fine Fragrance’s recovery is linked to managing Middle East uncertainty—Q2 finished slightly positive despite expected mid-single-digit decline, while management is factoring softer Q3 and planning for recovery into Q4. ²

Consumer Fragrance (Scent): low single-digit baseline in H2, normalization after strong Q2

Management characterized Consumer Fragrance as being in the low single-digit range for the second half. ³
They noted Q2 was unusually strong at high single-digit growth, but expect that to normalize going forward to low single-digit growth. ³
They also signaled that the R&D and commercial rebuild should underpin the longer-run trajectory by supporting market share gains. ³

Fragrance Ingredients (related evolution affecting overall Scent recovery, though not asked directly)

Management stated Fragrance Ingredients should normalize on a go-forward basis, and that it will be slightly under pressure year-over-year as part of the “calibration.” ³
They also said normalization is tied to the shift back to higher-value natural products, but that this shift will take more time and is not expected to be fully reflected in the second half; rather, it should improve competitiveness “as we go into next year and the year after.” ³

3) Plan for R&D to support 2027

A. Immediate R&D outcome: repaired pipeline, leading-edge capabilities, and delivery systems

Management explicitly tied the improvement to restoring R&D momentum: after a weak pipeline ~2.5 years ago, they now have strong R&D capability, a strong R&D team, great perfumers, and a pipeline of molecules and delivery systems. ⁴
This R&D ramp is positioned as directly supportive of Fine and Consumer Fragrances, as perfumers are developing “absolutely leading-edge new Fine Fragrances and Consumer Fragrances.” ⁴

B. Strategic intent: “reinvest” and sustain innovation as a compounding loop into 2027

Management emphasized the importance of maintaining reinvestment in R&D and commercial innovation as part of the “circle” that improves growth and ultimately supports margin expansion. ⁵
They cited that the R&D “percentage of sales” is in an 8% to 9% range and stressed the need to critically continue to reinvest. ⁵

C. Practical R&D/innovation mechanics: molecules + delivery systems + rebuilt go-to-market

The R&D capability description includes both molecules and delivery systems (i.e., not only discovery but also formulation/delivery innovation). ⁴
On the commercial side, management specifically called out rebuilding the go-to-market approach with customers alongside the R&D capability rebuild—an important link for converting R&D output into 2027-oriented market share gains. ³

D. Longer-run competitiveness expectation (2027-supporting positioning)

While the question asks for a “plan,” the excerpts provide a clear forward-looking stance: for Fragrance Ingredients (part of the Scent ecosystem), management says the higher-value natural products shift is underway but takes time and is expected to deliver a strong competitive position in the next year and the year after. ³
That “time-to-rotate” framing is consistent with how they describe Fine and Consumer Fragrance second-half moderation/normalization while believing R&D and pipeline improvements should translate into better positioning going beyond 2026. ³⁴

E. Leadership continuity and R&D resourcing/ownership

The company highlighted Ana Mendonça as the Scent leader with a team spanning Fine Fragrance, Consumer Fragrance, Fragrance Ingredients, and R&D teams, reinforcing organizational ownership of the R&D-to-business link. ⁴

Bottom line synthesis

Scent’s recovery is driven by (1) strong Q2 operating execution and volume/productivity, (2) Fragrance Ingredients leveraging synthetics during disruption (with a planned normalization toward higher-value inputs), (3) Fine Fragrance management of Middle East volatility with Q3 softness and Q4 recovery, and (4) Consumer Fragrance capability rebuilding—especially R&D capability and go-to-market—to drive market share gains. ²¹³⁴
In H2 2026, Fine Fragrance is expected to grow in the mid-single-digit range with Q3 softer / Q4 stronger, while Consumer Fragrance should be low single-digit, normalizing from a high single-digit Q2 baseline. ³
The R&D plan supporting 2027 is centered on the already-improving R&D system: a restored pipeline (molecules + delivery systems), leading-edge perfumer output, and sustained reinvestment (R&D intensity referenced at 8%–9% of sales) paired with a rebuilt customer go-to-market model to convert innovation into growth and competitiveness as the cycle matures beyond 2026. ⁴⁵³

References

International Flavors & Fragrances Inc. (IFF) earnings transcript 2026 - Q2

Disclaimer: The output generated by dafinchi.ai, a Large Language Model (LLM), may contain inaccuracies or "hallucinations." Users should independently verify the accuracy of any mathematical calculations, numerical data, and associated units, as well as the credibility of any sources cited. The developers and providers of dafinchi.ai cannot be held liable for any inaccuracies or decisions made based on the LLM's output.

Keep Reading

IFF Scent Recovery Gains Momentum in Q2 2026, H2 Growth and 2027 R&D Plan

IFF's Scent recovery is advancing on multiple fronts, led by volume-driven growth, a re-energized R&D pipeline, and stable management of regional volatility. In 2H, Fine Fragrance should soften in Q3 and rebound in Q4, while Consumer Fragrance normalizes to a low single-digit pace, with 2027 R&D investments positioned to bolster long-term competitive strength.

Sources used

Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?

Answer outline

Drivers of the Scent recovery (what changed and why it’s improving)
- Execution and growth momentum inside Scent (volume, productivity, wins)
- Fragrance Ingredients: strong Q2 performance, driven by tactical portfolio use, expected to normalize toward higher-value inputs
- Fine Fragrance: management contained Middle East volatility while expecting a Q3/Q4 shape
- R&D recovery: rebuilt pipeline and capability after being “behind” 2.5 years ago
How Fine Fragrance and Consumer Fragrance will evolve in 2H (direction, phasing, and growth ranges)
- Fine Fragrance evolution in 2H (Q3 softer, Q4 stronger; mid-single-digit 2H growth)
- Consumer Fragrance evolution in 2H (low single-digit; normalization after a strong Q2)
- Fragrance Ingredients (context, because it influences “Scent recovery”)
Plan for R&D to support 2027 (capability, pipeline, and go-to-market integration)
- R&D capability rebuilt: from falling behind to leading-edge pipeline and perfumer output
- B. “Go-to-market approach” and customer rebuilding are part of the R&D-to-market plan
- R&D investment is treated as a strategic pillar supporting future growth and margin—not a one-quarter fix
- Timing signals: normalization/transition today, stronger competitive position later (including 2027-supporting period)
Bottom line synthesis

Keep Reading

IFF Scent Recovery Gains Momentum in Q2 2026, H2 Growth and 2027 R&D Plan

Sources used

Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?

Answer outline

Drivers of the Scent recovery (what changed and why it’s improving)
- Execution and growth momentum inside Scent (volume, productivity, wins)
- Fragrance Ingredients: strong Q2 performance, driven by tactical portfolio use, expected to normalize toward higher-value inputs
- Fine Fragrance: management contained Middle East volatility while expecting a Q3/Q4 shape
- R&D recovery: rebuilt pipeline and capability after being “behind” 2.5 years ago
How Fine Fragrance and Consumer Fragrance will evolve in 2H (direction, phasing, and growth ranges)
- Fine Fragrance evolution in 2H (Q3 softer, Q4 stronger; mid-single-digit 2H growth)
- Consumer Fragrance evolution in 2H (low single-digit; normalization after a strong Q2)
- Fragrance Ingredients (context, because it influences “Scent recovery”)
Plan for R&D to support 2027 (capability, pipeline, and go-to-market integration)
- R&D capability rebuilt: from falling behind to leading-edge pipeline and perfumer output
- B. “Go-to-market approach” and customer rebuilding are part of the R&D-to-market plan
- R&D investment is treated as a strategic pillar supporting future growth and margin—not a one-quarter fix
- Timing signals: normalization/transition today, stronger competitive position later (including 2027-supporting period)
Bottom line synthesis

IFF Scent Recovery Fueled by Q2 Strength, R&D Push, and 2027 Plan

Sources used

Research question

Answer

IFF Scent recovery drivers, H2 evolution for Fine Fragrance & Consumer Fragrance, and R&D plan to support 2027

1) Drivers of Scent’s recovery

A. Strong underlying execution across Fine Fragrance, Consumer Fragrance, and Fragrance Ingredients

B. Fragrance Ingredients: synthetics capture + normalization toward higher-value ingredients

C. Fine Fragrance: operational management of Middle East volatility with a strong Q4 setup

D. Consumer Fragrance: R&D capability rebuild + go-to-market execution to regain share

E. R&D capability and pipeline progress is a concrete operational recovery lever

2) How Fine Fragrance and Consumer Fragrance will evolve in H2

Fine Fragrance (Scent): mid-single-digit range in H2 with Q3 softer and Q4 stronger

Consumer Fragrance (Scent): low single-digit baseline in H2, normalization after strong Q2

Fragrance Ingredients (related evolution affecting overall Scent recovery, though not asked directly)

3) Plan for R&D to support 2027

A. Immediate R&D outcome: repaired pipeline, leading-edge capabilities, and delivery systems

B. Strategic intent: “reinvest” and sustain innovation as a compounding loop into 2027

C. Practical R&D/innovation mechanics: molecules + delivery systems + rebuilt go-to-market

D. Longer-run competitiveness expectation (2027-supporting positioning)

E. Leadership continuity and R&D resourcing/ownership

Bottom line synthesis

References

Keep Reading

IFF Scent Recovery Gains Momentum in Q2 2026, H2 Growth and 2027 R&D Plan

Keep Reading

Keep Reading

IFF Scent Recovery Gains Momentum in Q2 2026, H2 Growth and 2027 R&D Plan

IFF's Scent Recovery Driven by R&D Upgrades, 2H Growth Outlook for 2027

IFF Scent Recovery Accelerates on Fragrance Ingredients, H2 Outlook, 2027 R&D Plan

IFF Scent Recovery Gains Momentum in Q2 2026; H2 Outlook and 2027 R&D Plan

IFF Scent Recovery Driven by Consumer Fragrance, H2 Outlook, and 2027 R&D Plan

IFF Scent Recovery Driven by Fragrance Ingredients, R&D Push for 2027

IFF Scent Recovery Driven by R&D, H2 Outlook, 2027 Plan

IFF Scent Recovery Fueled by 2H Fine Fragrance Growth and 2027 R&D Push

IFF's Scent Recovery Gains Momentum as R&D Lays 2027 Roadmap and 2H 2026 Outlook

IFF Scent Recovery Driven by R&D Rebuild; Q2 2026 H2 Outlook and 2027 Plan

IFF's Scent Recovery Q2 2026 Highlights, H2 Outlook and 2027 R&D Plan

IFF Guides Capex at 5–6% and R&D at 8–9% Post-Divestiture Growth